
ReproCELL Incorporated — Investor Relations & Filings
ReproCELL Incorporated is a global company providing solutions for preclinical and clinical research, with a primary focus on stem cell technology, drug discovery, and regenerative medicine. The company's portfolio includes a wide range of products such as induced pluripotent stem cells (iPSCs), differentiated cells, 3D cell culture models, and specialized reagents like RNA-based reprogramming kits that avoid genomic integration. ReproCELL also offers extensive contract research services, including human tissue assays for evaluating drug efficacy and safety. A key area of expertise is the GMP-compliant manufacturing of clinical-grade iPSCs and iPSC-derived mesenchymal stem cells (iMSCs), supporting the development of advanced cell therapies. The company's tools and services are designed to help academic and commercial scientists accelerate the translation of research into clinical applications.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 連結子会社(REPROCELL USA Inc.)に対する補助金の交付決定に関するお知らせ | 2026-05-22 | Japanese | |
| 確認書 | 2025-11-13 | Japanese | |
| 半期報告書-第24期(2025/04/01-2026/03/31) | 2025-11-13 | Japanese | |
| 内部統制報告書-第23期(2024/04/01-2025/03/31) | 2025-06-26 | Japanese | |
| 確認書 | 2025-06-26 | Japanese | |
| 有価証券報告書-第23期(2024/04/01-2025/03/31) | 2025-06-26 | Japanese |
Browse filings by year
12 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
1 filing
| |||||
| 46779402 | 連結子会社(REPROCELL USA Inc.)に対する補助金の交付決定に関するお知らせ | 2026-05-22 | Japanese | ||
|
2025
5 filings
| |||||
| 8284113 | 確認書 | 2025-11-13 | Japanese | ||
| 8284101 | 半期報告書-第24期(2025/04/01-2026/03/31) | 2025-11-13 | Japanese | ||
| 7246941 | 内部統制報告書-第23期(2024/04/01-2025/03/31) | 2025-06-26 | Japanese | ||
| 7246936 | 確認書 | 2025-06-26 | Japanese | ||
| 7246939 | 有価証券報告書-第23期(2024/04/01-2025/03/31) | 2025-06-26 | Japanese | ||
|
2024
9 filings
| |||||
| 7298959 | 確認書 | 2024-11-13 | Japanese | ||
| 7298954 | 半期報告書-第23期(2024/04/01-2025/03/31) | 2024-11-13 | Japanese | ||
| 7325542 | 臨時報告書 | 2024-06-26 | Japanese | ||
| 7328563 | 内部統制報告書-第22期(2023/04/01-2024/03/31) | 2024-06-25 | Japanese | ||
| 7328560 | 確認書 | 2024-06-25 | Japanese | ||
| 7328561 | 有価証券報告書-第22期(2023/04/01-2024/03/31) | 2024-06-25 | Japanese | ||
| 7336087 | 臨時報告書 | 2024-05-23 | Japanese | ||
| 7356961 | 確認書 | 2024-02-09 | Japanese | ||
| 7356958 | 四半期報告書-第22期第3四半期(2023/10/01-2023/12/31) | 2024-02-09 | Japanese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
BioInfra Life Science Inc.
Develops multi-biomarker blood tests for early cancer scree…
|
266470 | KR | Professional, scientific and te… |
|
Biomark Diagnostics Inc.
Oncology liquid biopsy diagnostics using metabolomics and A…
|
BUX | CA | Professional, scientific and te… |
|
Biomind Labs
Developing novel pharmaceutical drugs for patients with neu…
|
BMND | CA | Professional, scientific and te… |
|
BioNexus Gene Lab Corp
Develops gene-based diagnostics for early detection of dise…
|
BGLC | US | Professional, scientific and te… |
|
Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-rela…
|
ALBPS | FR | Professional, scientific and te… |
|
BioRestorative Therapies, Inc.
Develops adult stem cell therapies for degenerative disc an…
|
BRTX | US | Professional, scientific and te… |
|
BioSenic SA
Develops therapies for autoimmune diseases, inflammation, a…
|
BIOS | BE | Professional, scientific and te… |
|
BIOTECH
A biotechnology group offering preclinical services, intein…
|
BST | ES | Professional, scientific and te… |
|
BIOTRON LIMITED
Clinical-stage developer of small molecule antiviral drugs …
|
BIT | AU | Professional, scientific and te… |
|
BioVaxys Technology Corp.
Clinical-stage biopharma developing novel immunotherapy ass…
|
BIOV | CA | Professional, scientific and te… |
ReproCELL Incorporated via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/13724/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=13724 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=13724 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=13724 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 13724}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ReproCELL Incorporated (id: 13724)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.